کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
4001189 1259399 2006 8 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی تومور شناسی
پیش نمایش صفحه اول مقاله
Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells
چکیده انگلیسی

Dendritic cells from patients with cancer are deficient in number and functional activity, leading to inadequate tumor immunosurveillance as a result of poor induction of T-cell antitumor responses. Loaded dendritic cell therapy is a vaccination strategy aimed at eliciting tumor antigen-specific, T-cell immune responses. Loaded dendritic cell therapy using prostatic acid phosphatase (APC8015; Provenge®, Dendreon Corp., Seattle, WA) as an immunogen has shown a survival benefit in patients with metastatic hormone-refractory prostate cancer in a randomized phase III trial. This review will summarize the prostate cancer clinical trials using APC8015 and discuss the potential future role of APC8015 in prostate cancer treatment.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Urologic Oncology: Seminars and Original Investigations - Volume 24, Issue 5, September–October 2006, Pages 434–441
نویسندگان
, , ,